1.92  0.09 (4.92%)		06-16 15:58
Open: 1.89 High: 1.92 Volume: 18,557		Pre. Close: 1.83 Low: 1.7608 Market Cap: 22(M)

Short term
Mid term
Targets	6-month :	2.88	1-year :	4.67
Resists	First :	2.47	Second :	4
Pivot price	1.82
Supports	First :	0	Second :	0
MAs	MA(5) :	1.91	MA(20) :	1.81
	MA(100) :	0	MA(250) :	0
MACD	MACD :	0	Signal :	0
%K %D	K(14,3) :	76.9	D(3) :	73.2
RSI	RSI(14): 70.9
52-week	High :	4	Low :	1.44

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ APUS ] has closed below upper band by 21.1%. Bollinger Bands are 0% narrower than normal.

If tomorrow:	Open lower	Open higher
High:	1.92 - 1.93	1.93 - 1.94
Low:	1.74 - 1.75	1.75 - 1.76
Close:	1.9 - 1.92	1.92 - 1.94

Apimeds Pharmaceuticals US, Inc. operates as a clinical stage biopharmaceutical company in the United States. It researches, develops, manufactures, commercializes, and sells Apitox, an active pharmaceutical ingredient for the treatment of inflammation and pain management symptoms associated with osteoarthritis and multiple sclerosis. The company was incorporated in 2020 and is based in Hopewell, New Jersey. Apimeds Pharmaceuticals US, Inc. is a subsidiary of Api Meds, Inc.

Fri, 13 Jun 2025
WTR Biotech Spotlight Podcast Recap Apimeds Pharmaceuticals US, Inc. (APUS) - Smartkarma

Tue, 10 Jun 2025
Biopharma financings rise to $5.55B in May, with VC deals at $1.83B - BioWorld MedTech

Thu, 29 May 2025
D. Boral Capital Acted as Sole Bookrunner to Apimeds Pharmaceuticals US, Inc. (NYSE:APUS) in connection with its $13.5 Million Initial Public Offering - Lohud

Fri, 16 May 2025
D. Boral Capital Acted as Sole Bookrunner to Apimeds Pharmaceuticals US, Inc. (NYSE:APUS) in connection with its $13.5 Million Initial Public Offering - ACCESS Newswire

Mon, 12 May 2025
Apimeds Pharmaceuticals US, Inc. Announces Closing of Initial Public Offering - Stock Titan

Mon, 12 May 2025
Apimeds Pharmaceuticals US, Inc. Completes Initial Public Offering, Raising $13.5 Million for Clinical Development - Nasdaq

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NYSE
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Shares Out	0 (M)
Shares Float	0 (M)
Held by Insiders	0 (%)
Held by Institutions	0 (%)
Shares Short	0 (K)
Shares Short P.Month	0 (K)

EPS	0
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	0 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	0 (M)

PE Ratio	0
PEG Ratio	0
Price to Book value	0
Price to Sales	0
Price to Cash Flow	0

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.